BIO: venture funding favors novel R&D

The Biotechnology Industry Organization intends to release a report on Tuesday concerning disbursements of venture capital in the drug R&D sector.

The report, 'Venture Funding of Therapeutic Innovation,' said 78% of U.S. venture capital for drug R&D during 2004-13 was invested in novel therapeutics rather than improvements upon existing drugs. Novel therapies were defined as new chemical entities with no prior regulatory approval, while drug improvement R&D included development of new delivery methods, new formulations and new indications for approved drugs. ...